Bone marrow toxicities in ovarian cancer patients treated with parp inhibitors

Introduction and aim of the study: PARP inhibitors (olaparib, niraparib) significantly improve the prognosis of patients with ovarian cancer. We aimed to analyze the hematological side effects of the patients treated with olaparib and niraparib.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Source Type: research